Evotec Se (OP:EVOTF)

3.325 UNCHANGED

Delayed Quote Updated: 10:21 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evotec Se

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

January 07, 2024

Via ACCESSWIRE

Apple Loses Appeal Over 4G Patent Infringement In London Court, AI Can Drive TSMC's Revenue Rebound, Alibaba Conducts Strategic Review of Youku and Tudou Amidst Rivalry: Today's Top Stories ↗

July 05, 2023

Reuters

Via Benzinga

Evotec Secures US Government Contract For Orthopoxvirus Antibody ↗

July 05, 2023

The U.S.

Via Benzinga

Adapsyn Bioscience Inks Collaboration Pact With Evotec ↗

September 21, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Evotec Enters a Drug Discovery Collaboration with Janssen

June 14, 2022

HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen...

From Evotec SE

Via AccessWire

Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

May 19, 2022

HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global...

From Evotec AG

Via AccessWire

Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures

April 12, 2022

- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY...

From Evotec AG

Via AccessWire

Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb

April 08, 2022

- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A...

From Evotec AG

Via AccessWire

Why Are Evotec Shares Trading Lower On Friday? ↗

February 04, 2022

Bayer AG (OTC: BAYRY) has

Via Benzinga

Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic

January 03, 2022

- EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 - EVOTEC IS DEVELOPING A HIGHLY POTENT...

From Evotec AG

Via AccessWire

Germany Based Evotec Sets Terms For $576M US IPO ↗

October 27, 2021

German biotech Evotec SE (OTC: EVTCY) plans to raise $576 million by offering 22 million ADSs at $26.16. At the proposed price, Evotec would command a market value of $...

Via Benzinga

Pasithea, Evotec Ink Drug Development Pact ↗

October 11, 2021

Pasithea Therapeutics Corp (NASDAQ: KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research...

Via Benzinga

Evotec Expands Neuroscience Collaboration with Bristol Myers ↗

October 08, 2021

Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related:...

Via Benzinga

Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate ↗

September 02, 2021

Evotec SE (OTC: EVTCY) says that Bristol Myers Squibb Co (NYSE: BMY) has exercised its option to enter into an exclusive global license for EVT8683. It...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.